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Abstract
Background: The exact pathophysiology of atrial fibrillation (AF) remains incom-
pletely understood and treatment of AF is associated with high recurrence rates. Per-
sistence of AF is rooted in the presence of electropathology, defined as complex
electrical conduction disorders caused by structural damage of atrial tissue. The atrial
fibrillation fingerprinting (AFFIP) study aims to characterize electropathology,
enabling development of a novel diagnostic instrument to predict AF onset and early
progression.
Hypotheses: History of AF, development of post-operative AF, age, gender, underly-
ing heart disease, and other clinical characteristics impact the degree of
electropathology.
Methods: This study is a prospective observational study with a planned duration of
48 months. Three study groups are defined: (1) patients with (longstanding) persistent
AF, (2) patients with paroxysmal AF, and (3) patients without a history of AF, all
undergoing open-chest cardiac surgery. Intra-operative high-resolution epicardial
mapping is performed to identify the patient-specific electrical profile, whereas the
patient-specific biological profile is assessed by evaluating proteostasis markers in
blood samples and atrial appendage tissue samples. Post-operative continuous
rhythm monitoring is performed for detection of early post-operative AF. Late post-
operative AF (during 5-year follow-up) is documented by either electrocardiogram or
24-hour Holter registration.
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Trial registrations: Rotterdam Medical Ethical Committee MEC-2014-393 (27-Oct-2014), Netherlands Trial Register NL4524 (12-Jun-2014).
Abbreviations: AF, atrial fibrillation; AFFIP, atrial fibrillation fingerprinting; BB, Bachmann's bundle; CFP, complex fractionated potential; HSP, heat shock protein; ICV, inferior caval vein; LA, left
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Results: The required sample size for this study is estimated at 447 patients. Up till
now, 105 patients were included, of whom 36 have a history of AF.
Conclusion: The AFFIP study will elucidate whether electrophysiological and struc-
tural characteristics represent a novel diagnostic tool, the AF fingerprint, to predict
onset and early progression of AF in cardiac surgery patients.
K E YWORD S
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1 | INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia worldwide,
and its incidence1 and associated medical health care costs2 continuously
increase. Even though numerous predisposing factors for progression of
AF have been identified, the exact pathophysiology remains incompletely
understood and treatment of AF is associated with high recurrence rates.
As disease progression from recurrent intermittent episodes to finally per-
manent AF is accompanied by a gradual increase in therapy failure, early
recognition of AF is of prime importance. Persistence of AF is rooted in
the presence of electropathology, which is defined as complex electrical
conduction disorders caused by structural damage of atrial tissue. There-
fore, early recognition of AF susceptibility in patients is necessary to halt
electropathology and hence disease onset and progression. Although
promising artificial intelligence applications are emerging,3 up till this day
in clinical practice, AF is diagnosed with a surface electrocardiogram when
a patient already suffers from AF. This rhythm registration cannot assess
the degree of electropathology and thus the stage of AF which is essen-
tial for selection of the appropriate therapy. Hence, early recognition of
AF and the start of effective treatment is seriously hampered. By charac-
terizing electropathology, we aim to develop a novel diagnostic instru-
ment to predict AF onset and early progression. We hypothesize that
every patient has a unique biological and electrical signal profile that is
influenced by age, gender and underlying heart disease. This bio-electrical
profile is deduced from the ratio abnormal/normal electrical signals in the
atria by utilizing a unique high-density atrial mapping approach and deter-
mination of proteostasis markers in tissue or blood samples related to
structural damage. These outcomes are summarized in an AF Fingerprint.
Multi-site high density epicardial mapping has been used in multi-
ple research protocols in Rotterdam (QUASAR study MEC 2010-054,
HALT&REVERSE study MEC 2015-393), Leiden and Maastricht.4-7
Since 2010, the mapping procedure is daily practice in the Erasmus
Medical Center. Atrial conduction during both sinus rhythm (SR) and
(induced) AF can be visualized to identify the patient-specific electri-
cal profile. This alone however does not clarify electropathological
changes on structural level that contribute to substrate for
AF. Previous studies revealed that structural damage is caused by
derailment of protein homeostasis due to loss of key modulators
within the protein quality system.8 Failure of protein quality control in
AF involves impairment of heat shock proteins (HSPs),9 autophagy,10
loss of sarcomeric and microtubule proteins,11,12 and activation of
DNA damage/PARP1/NAD axis,13 favoring progression of AF.
The AFFIP study combines electrophysiological and structural
alterations into one AF fingerprint (Figure 1). Electrophysiological data
obtained from epicardial mapping during surgery are combined with
proteostasis markers on one hand and atrial tissue characteristics on
the other hand. By comparing the bio-electrical AF fingerprint of
patients from different age groups, gender, history of AF, develop-
ment of post-operative AF, underlying heart disease and other clinical
characteristics, we hope to gain more insight in the mechanism under-
lying AF and the development of a substrate for AF. The findings will
elucidate whether structural and electrophysiological characteristics
represent a novel diagnostic tool, the AF fingerprint, to predict onset
and early progression of AF in cardiac surgery patients.
2 | METHODS
AFFIP is a prospective observational study, with a planned duration of
48 months. This study is carried out according to the principals of the
Declaration of Helsinki and in accordance with the Medical Research
involving Human Subjects Acts. The study is part of the
HALT&REVERSE protocol which is approved by the Rotterdam local
medical ethical committee (MEC-2014-393).
2.1 | Study objectives
The primary study objectives are to test the correlation between the
AF fingerprint, revealing the degree of electropathology including for
example, patterns of activation and signal morphology, proteostasis
levels and atrial tissue characteristics, clinical characteristics and onset
and progression of AF in patients undergoing open-chest cardiac
surgery.
2.2 | Study population
Patients with structural heart disease scheduled for elective cardiac
surgery are included. The study population consists of three study
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groups: patients with (longstanding) persistent AF (group 1), patients
with paroxysmal AF (group 2) and patients without a history of AF
(group 3) undergoing open-chest cardiac surgery. In line with ESC
guidelines, patients with documentation (ECG or ECG description) of
self-terminating AF episodes up to 7 days, or with AF episodes
cardioverted within 7 days are classified as paroxysmal AF. Patients
with documentation of AF episodes longer than 7 days or longer than
a year are classified as persistent and longstanding persistent AF,
respectively. Patients are recruited at the Department of Cardiotho-
racic Surgery at the Erasmus Medical Center, Rotterdam, The Nether-
lands. Prior to enrolling in the study, each patient is provided an oral
and a written explanation of the study procedure. Written informed
consent is obtained from all patients.
Prior to cardiac surgery, blood samples are taken from all patients
for determination of proteostasis levels (Figure 2). Patient characteris-
tics (eg, age, medical history, and cardiovascular risk factors) are
obtained from the patient's file.
2.3 | Inclusion criteria
In order to be eligible to participate in this study, a subject must
meet all of the following criteria:
• at least 18 years of age;
• structural heart disease (with or without history of AF); and
• scheduled for elective cardiac surgery.
2.4 | Exclusion criteria
A potential subject who meets any of the following criteria is excluded
from participation in this study:
• hemodynamic instability;
• emergency cardiac surgery; and
F IGURE 1 Concept of the atrial
fibrillation fingerprinting (AFFIP)
study. The AFFIP study hypothesizes
that every patient has a unique
biological and electrical signal profile
that is influenced by age, gender and
heart disease. Intra-operative high-
resolution epicardial mapping is
performed to identify the patient-
specific electrical profile, whereas the
biological profile is assessed by
evaluating proteostasis levels in blood
samples and atrial appendage tissue
samples. Derailment of protein
homeostasis can lead to structural
remodeling, favoring inhomogeneous
conduction and progression of atrial
fibrillation (AF). We aim to develop a
novel diagnostic tool, the bio-
electrical AF Fingerprint, to predict
onset and early progression of AF
F IGURE 2 Time course of the atrial fibrillation fingerprinting (AFFIP) study. A baseline blood sample (red bar) is obtained from all patients
1 day prior to surgery. During surgery, the study procedure (blue bar, epicardial mapping) is performed, followed by post-operative continuous
rhythm monitoring (orange bar). Patients are consulted by phone at 6 months, 12 months, and yearly up to 5 years after surgery for detection of
late post-operative atrial fibrillation (AF) (green bars)
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• redo-cardiac surgery.
Additional details of entry criteria are listed in the Appendix S1.
2.5 | Intra-operative mapping procedure
Epicardial mapping is performed during surgery. Patients are under full
anesthesia and vital signs are monitored continuously throughout the
procedure. Epicardial unipolar electrograms are recorded using a
custom-made multi-site electrode array. Recordings are made at nine
consecutive sites (right atrium 1-4, Bachmann's bundle, right and left
pulmonary vein, and left atrium 1-2), following a predefined mapping
scheme (Figure 3) during SR (nine sites, 5 seconds/site), during pacing
maneuvers for inducing AF (one site, Bachmann's bundle), and in AF
(nine sites, 10 seconds/site). Pacing is performed with atrial fixed rate
pacing directly from the electrode or with a standard temporary
pacemaker wire. If AF sustains at the end of the mapping procedure,
SR is restored with 5-10 J electrical cardioversion.
After introduction of the extra corporal circulation into the right
atrium via the right atrial appendage (RAA) a tissue sample (approxi-
mately 10 × 10mm) is obtained from the incision site in all patients. In
patients undergoing mitral valve surgery, the left atrial appendage
(LAA) is also incised and a small tissue sample is excised. In patients
undergoing surgical pulmonary vein isolation, a left sided procedure in
patients with AF which includes amputation of the LAA, the LAA tis-
sue is also studied.
2.6 | Follow-up
After procedure, the heart rhythm is continuously monitored until
hospital discharge in order to detect early post-operative AF. Patients
are also consulted by phone at 6 months, 12 months, and yearly up to
F IGURE 3 Epicardial mapping to retrieve unipolar atrial electrograms. With the use of a 192 electrode arrays, the left atrium (LA), right atrium
(RA), pulmonary vein (PV) area, and Bachmann's bundle (BB) are mapped following this predefined mapping scheme. Unipolar atrial electrograms
are collected during sinus rhythm (SR), pacing maneuvers (P), and (electrically induced) atrial fibrillation (AF). Morphology of atrial potentials are
subdivided into four categories: single potentials (one deflection), short double potentials (two deflections less than 15 ms apart), long double
potentials (two deflections 15 ms or more apart), and complex fractionated potentials (three or more deflections). ICV, inferior caval vein; LAA,
left atrial appendage; PVL, left pulmonary vein area; PVR, right pulmonary vein area; RAA, right atrial appendage; SCV, superior caval vein
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5 years after surgery in order to detect late post-operative AF
(Figure 2). If post-operative AF is suspected, documentation of elec-
trocardiography, 24-hour Holter registration or a clinical discharge let-
ter from peripheral hospitals are retrieved.
2.7 | Tissue analysis
All obtained blood samples and atrial tissue samples are stored at
-80C until transport to the Amsterdam UMC, location VU Medical
Center. Proteostasis markers include HSP27, HSP70, HSPA1A,
HSPA5, HSPB1, HSPB5, HSPB6, HSPB7, HSPB8, HSPD1, α-SMA,
LC3B-II, TIMP1, LOX3, MMP9, Galectin-3, NCAM, MT-ND1, and
COX3, and are determined by commercially available ELISAs and
Western blot analysis at the Department of Physiology of the
Amsterdam UMC.
2.8 | Main study parameters and endpoints
Primary endpoint of the study is development or recurrence of
AF. Secondary endpoints include implantation of an atrial pacemaker
or implantable cardioverter defibrillator. Additional secondary end-
points are described in the Appendix S1. At present, no substudies are
planned.
Deflections of the recorded atrial electrograms are detected
semi-automatically in custom-made Python 3.6 software. In case of
fractionated electrograms, the component with the steepest negative
slope is taken as the local activation time (Figure 3). Electrograms with
injury potentials and artifacts are excluded from analysis by consensus
of two investigators. Signals are used to construct color-coded activa-
tion, conduction block, break-through wave, fractionation, and voltage
maps (Figure 4). Furthermore, the relation between patterns of activa-
tion, incidence of breakthrough waves, fractionation, fibrillation inter-
vals, conduction abnormalities, and voltage is studied and compared
between the different atrial sites and atrial rhythms. Electrical changes
as defined with the above-mentioned electrical parameters will be
correlated with the pre-operative proteostasis levels, development of
post-operative AF, age, gender, and other clinical characteristics.
The primary hypothesis is that the degree of electropathology will
be increased in patients with a history of AF and patients whom
develop post-operative AF. Secondarily, we hypothesize that age,
gender, underlying heart disease and other clinical characteristics
impact the degree of electropathology.
2.9 | Sample size calculation
Based upon our experience in prior mapping studies approximately
30% of patients develop early post-operative AF in the Erasmus
MC,13 which is in correspondence with published literature.14
There is no data on the proposed novel electrophysiological
parameters and biomarkers, and calculation of the sample size is
therefore at present not possible. However, we used data obtained
F IGURE 4 Construction of the
atrial fibrillation fingerprint (AFFIP).
The left panel shows an example of
an activation map during electrically
induced atrial fibrillation (AF) of the
left pulmonary vein area in a patient
undergoing coronary artery bypass
grafting without a history of
AF. Isochrones are drawn at 5 ms,
areas of conduction block (Δ local
activation time [LAT] ≥ 12 ms) are
indicated by black bars and the origin
of peripheral waves by gray dots. The
arrows indicate main activation
direction. The corresponding
fractionation map is displayed in the
right panel and shows the different
types of atrial potential morphologies:
single potentials (SP, one deflection),
short double potentials (sDP, two
deflections less than 15 ms apart),
long double potentials (lDP, two
deflections 15 ms or more apart) and
complex fractionated potentials (CFP,
three or more deflections). The maps
are used to determine the incidence
of for example, fractionation and
conduction block
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from a pilot study containing five patients with and five patients with-
out AF. With a P value of 0.05 and a chosen power of 0.95 the
required number is 135 per study group. An attrition rate of 10%
increases this to 149 patients in each group. The required sample size
for this study is therefore estimated at 447 patients. These calcula-
tions will be repeated after the first 50 patients in every group in
order to adjust the sample size.
2.10 | Statistical analysis
Associations between proteostasis markers, electrical signals and clini-
cal patient outcomes are calculated using multivariate logistic regres-
sion and cox regression models. Log rank tests compare patient
groups with different stages of AF. Continuous and categorical elec-
trophysiological parameters are compared with respectively ANOVA
and chi-square tests. For repeated biomarker measurements, joint
modeling and mixed modeling analysis is used. ANOVA with
Bonferroni adjustments corrects for analysis of multiple biomarkers.
2.11 | Study organization
This multi-disciplinary study is carried out by dedicated teams, whom
are responsible for the following tasks:
Translational Electrophysiology Research Unit of the Department
of Cardiology at the Erasmus Medical Center, Rotterdam, The Nether-
lands: patient screening and recruitment, collection of electrophysio-
logical data during intra-operative mapping procedure, collection of
blood samples, patient follow-up, electrophysiological data analyses,
and statistical analyses.
Department of Cardiothoracic Surgery at the Erasmus Medical Cen-
ter, Rotterdam, The Netherlands: intra-operative mapping procedure and
collection of atrial tissue samples during open-chest cardiac surgery.
Atrial Fibrillation Research Unit of the Department of Physiology
at the Amsterdam UMC, Amsterdam, The Netherlands: analysis of
biological markers from tissue and blood samples.
Trial Office of the Department of Cardiothoracic Surgery, Eras-
mus Medical Center, Rotterdam, The Netherlands: data safety
monitoring.
Supervision and steering of these teams is done by N.M.S.d.G.,
B.J.J.M.B., and A.J.J.C.B. Prof. Eric Boersma of the Department of
Clinical Epidemiology at the Erasmus Medical Center, Rotterdam, The
Netherlands, supervises all statistical analyses.
A detailed list of team members is included in the Appendix S1.
3 | RESULTS
The AFFIP study started in January 2017. The first patient enrolled on
January 27, 2017, and up till now 105 patients were included (as of
March 20, 2020), of whom 36 have a history of AF. Table 1 provides
the preliminary baseline characteristics of all enrolled patients.
4 | DISCUSSION
In clinical practice, AF is currently diagnosed with a surface electrocar-
diogram when a patient already suffers from AF. This rhythm registra-
tion cannot assess the degree of electropathology and thus the stage
of AF which is essential for selection of the appropriate therapy.
Hence, early recognition of AF and the start of effective treatment is
seriously hampered. The AFFIP study aims to characterize electro-
pathology, enabling development of a novel diagnostic instrument to
predict AF onset and early progression. Electrophysiological data
obtained from epicardial mapping during surgery are combined with
proteostasis markers on one hand and atrial tissue characteristics on
the other hand. The findings will elucidate whether electrophysiologi-
cal and structural characteristics represent a novel diagnostic tool, the
AF fingerprint, to predict onset and early progression of AF in patients
who had cardiac surgery.
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TABLE 1 Preliminary baseline characteristics of enrolled patients
(as of March 20, 2020)
Number of patients 105
Male 70 (67%)
Age (years) 64 (54-71)
BMI 27.2 (24.6-30.1)
Underlying heart disease
CABG 16 (15)
AVD 18 (16)
MVD 11 (10)
CABG + AVD 8 (8)
CABG + MVD 4 (4)
AVD + MVD 4 (4)
CHD 44 (42)
History of AF 36 (34)
Paroxysmal 20 (56)
Persistent 14 (39)
Longstanding persistent 2 (6)
Hypertension 48 (46)
Dyslipidemia 26 (25)
Diabetes mellitus 16 (15)
Note: Values are presented as N (%) or median (25th to 75th percentile).
Abbreviations: AVD, aortic valve disease; BMI, body mass index; CABG,
coronary artery bypass grafting; CHD, congenital heart disease; MVD,
mitral valve disease.
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